Antiviral therapy in HCV-infected cirrhotics awaiting liver transplantation: A costly strategy for mixed virological results.
Roche
Bruno
B
Samuel
Didier
D
D000998:Antiviral Agents / Q000009:adverse effects*; D001424:Bacterial Infections / Q000453:epidemiology*; D006526:Hepatitis C / Q000188:drug therapy* / Q000517:prevention & control / Q000601:surgery*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects / Q000627:therapeutic use; D016031:Liver Transplantation; D011092:Polyethylene Glycols / Q000009:adverse effects / Q000627:therapeutic use; D011994:Recombinant Proteins; D012254:Ribavirin / Q000009:adverse effects / Q000627:therapeutic use; D012449:Safety; D014850:Waiting Lists
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C100416:peginterferon alfa-2a